Ramucirumab plus erlotinib tolerable despite AEs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Nadal E, et al. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability Drug Safety : 20 Dec 2021. Available from: URL: https://doi.org/10.1007/s40264-021-01127-2